Evaluation of Anemia Medication Use in One-Day Care Patients with Chronic Kidney Disease at the Hemodialysis Unit of RSUD Dr. Achmad Mochtar Bukittinggi

Background: Chronic Kidney Disease (CKD) is a progressive impairment of renal function that frequently triggers renal anemia complications due to decreased erythropoietin hormone production. At RSUD Dr. Achmad Mochtar Bukittinggi, the service load of the Hemodialysis Unit is exceptionally high, making the evaluation of anemia therapy rationality crucial to ensure treatment efficacy. Objective: To evaluate patient characteristics, drug use patterns, and the level of drug use rationality for anemia therapy in One Day Care CKD patients undergoing hemodialysis. Methods: This descriptive observational study with a prospective approach involved 120 end-stage CKD respondents in January 2026. Data were collected through structured interviews and medical data verification. Results: The findings showed that respondents were predominantly male (59.17%), with the highest age group being 56–65 years old (30.83%). The therapeutic pattern indicated 100% erythropoietin use, 90.00% folic acid, 5.83% blood booster tablets, and 1.67% Sangobion. Rationality evaluation based on the 4T indicators (Right Patient, Right Drug, Right Indication, Right Dosage) demonstrated that correct patient, drug, and indication reached 100%. However, dosage accuracy was only 10.00%, where 90.00% of patients received a folic acid dose of 1–3 mg/day, which falls below the hospital's Clinical Practice Guidelines (CPG) standard of 5 mg/day. Conclusion: Overall, anemia therapy was appropriate regarding the right patient, right drug, and right indication, but requires significant correction in the folic acid dosage regimen.